A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors
A Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors (TKIs) in the Patients With Non-small Cell Lung Cancer Complicated With Brain Metastases
Sponsor: LinkDoc Technology (Beijing) Co. Ltd.
This observational or N/A phase trial investigates Non-small Cell Lung Cancer Metastatic and is currently ongoing. LinkDoc Technology (Beijing) Co. Ltd. leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LinkDoc Technology (Beijing) Co. Ltd.
- Tang-Du Hospital
For direct contact, visit the study record on ClinicalTrials.gov .